Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | PDE4B | Q07343 | 8/20 | 0.57 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.57 |
| ▸ | FDPS | P14324 | 1/20 | 0.55 |
| ▸ | TTR | P02766 | 1/20 | 0.51 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.50 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.50 |
| ▸ | ABAT | P80404 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847455 | 0.98 | ALDH1A1 (0.62) | ALDH1A1TSHRPDE4BPDE3AFDPS | |
| SCHEMBL70835 | 0.94 | ALDH1A1 (0.64) | ALDH1A1TSHRPDE4BPDE3APDE4A | |
| SCHEMBL7560477 | 0.94 | ALDH1A1 (0.64) | ALDH1A1TSHRPDE4BPDE3APDE4A | |
| SCHEMBL29808190 | 0.94 | ALDH1A1 (0.64) | ALDH1A1TSHRPDE4BPDE3APDE4A | |
| SCHEMBL13522989 | 0.94 | ALDH1A1 (0.68) | ALDH1A1TSHRPDE4BPDE3AFDPS | |
| SCHEMBL4637156 | 0.92 | ALDH1A1 (0.62) | ALDH1A1TSHRPDE4BPDE3APDE4A | |
| SCHEMBL6883557 | 0.92 | ALDH1A1 (0.66) | ALDH1A1TSHRPDE4BPDE3AFDPS | |
| SCHEMBL8845986 | 0.90 | PDE4B (0.49) | ALDH1A1TSHRPDE4BPDE3APDE4A | |
| SCHEMBL5905463 | 0.89 | PDE4B (0.48) | ALDH1A1TSHRPDE4BPDE3APDE4A | |
| SCHEMBL22713946 | 0.87 | ALDH1A1 (0.68) | ALDH1A1TSHRPDE4BPDE3AFDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109855-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B.G. NEGEV TECHNOLOGIES & APPLICATIONS LTD. AT BEN-GURION UNIVERSITY (IL) | 2024-04-04 | — | — | US | disclosed |
| EP-4277896-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University (IL) | 2023-11-22 | — | — | EP | disclosed |
| WO-2023018560-A1 | BICYCLIC FUSED PYRAZOLE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY INFECTIONS INCLUDING RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
| CN-109562160-B | Bicyclic fused pyrazole derivatives for the treatment of RSV | 乔治亚州立大学研究基金会股份有限公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022153306-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-07-21 | — | — | WO | disclosed |
| US-20210040066-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES (CN) | 2021-02-11 | — | — | US | disclosed |
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| EP-3750886-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019154395-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 中国科学院上海药物研究所 | 2019-08-15 | — | — | WO | disclosed |
| US-6248743-B1 | ANTITHROMBOTIC AGENTS EFFECTIVE TO INHIBIT THE PRODUCTION OF TYPE 1 PLASMINOGEN ACTIVATOR INHIBITOR (PAI-1) | TANABE SEIYAKU CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6248768-B1 | PROSTAGLANDIN INHIBITOR; ANTIINFLAMMATORY AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2001-06-19 | — | — | US | disclosed |
| US-6180644-B1 | TUMOR NECROSIS FACTOR INHIBITOR; ANTIINFLAMMATORY AGENT | CELGENE CORPORATION | 2001-01-30 | — | — | US | disclosed |
| EP-1060173-A2 | BENZAZINE DERIVATIVES PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.p.A. (IT) | 2000-12-20 | — | — | EP | disclosed |
| EP-0974589-A1 | BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TAIHO PHARMACEUTICAL COMPANY, LIMITED (JP) | 2000-01-26 | — | — | EP | disclosed |
| US-5968945-A | Immunotherapeutic agents | CELGENE CORPORATION (US) | 1999-10-19 | — | — | US | disclosed |
| WO-1999032449-A2 | BENZAZINE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS | ZAMBON GROUP S.P.A. (IT) | 1999-07-01 | — | — | WO | disclosed |
| CN-1214678-A | Butadiene derivatives and process for preparing thereof | TANABE SEIYAKU CO (JP) | 1999-04-21 | — | — | CN | disclosed |
| EP-0889879-A1 | BUTADIENE DERIVATIVES AND PROCESS FOR PREPARING THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 1999-01-13 | — | — | EP | disclosed |
| WO-1997036864-A1 | BUTADIENE DERIVATIVES AND PROCESS FOR PREPARING THEREOF | TANABE SEIYAKU CO., LTD. (JP) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109855-A1 | ANTI-QUORUM SENSING, ANTI-BIOFILM, AND INFLAMMATION ATTENUATING COMPOUNDS, COMPOSITIONS, AND METHODS OF USING SAME | FPR1, FPR2, IL1B | ALDH1A1 2719/4885TSHR 4219/4885PDE4B 680/4885 |
| US-10906899-B2 | Bicyclic fused pyrazole derivatives for the treatment of RSV | NIPSNAP3A, ZC3HAV1, SARNP | ALDH1A1 4237/4885TSHR 3818/4885PDE4B 3946/4885 |
| US-20210040066-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PDE4B, PDE7B, PDE4A | ALDH1A1 1376/4885TSHR 4492/4885PDE4B 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.